Deferiprone as Parkinson's disease modifier: quantification of 3-O-methyldopa/l-dopa plasmatic ratio in patients

被引：0
|
作者：
Charbonnier-Beaupel, F. [1 ]
Bihan, K. [1 ]
Zahr, N. [1 ]
Corvol, J. C. [1 ]
Devos, D. [2 ]
机构：
[1] Pitie Salpetriere, Paris, France
[2] CHU Lille, F-59037 Lille, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2013年 / 27卷
关键词：
Parkinson's disease; deferiprone; disease modifier; metabolic ratio;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：73 / 74
页数：2
相关论文
共 50 条
  • [1] The role of 3-O-methyldopa in the side effects of L-dopa
    Lee, Eun-Sook Y.
    Chen, Hongtao
    King, Jennifer
    Charlton, Clivel
    NEUROCHEMICAL RESEARCH, 2008, 33 (03) : 401 - 411
  • [2] The Role of 3-O-Methyldopa in the Side Effects of l-dopa
    Eun-Sook Y. Lee
    Hongtao Chen
    Jennifer King
    Clivel Charlton
    Neurochemical Research, 2008, 33 : 401 - 411
  • [3] 3-O-Methyldopa inhibits astrocyte-mediated dopaminergic neuroprotective effects of L-DOPA
    Asanuma, Masato
    Miyazaki, Ikuko
    BMC NEUROSCIENCE, 2016, 17
  • [4] The Effect of L-dopa on Postural Stability in Parkinson's Disease Patients
    Wilczynski, Jacek
    Habik, Natalia
    APPLIED SCIENCES-BASEL, 2019, 9 (03):
  • [5] Pupillometry as an indicator of l-DOPA dosages in Parkinson’s disease patients
    O. Bartošová
    C. Bonnet
    O. Ulmanová
    M. Šíma
    F. Perlík
    E. Růžička
    O. Slanař
    Journal of Neural Transmission, 2018, 125 : 699 - 703
  • [6] Pupillometry as an indicator of L-DOPA dosages in Parkinson's disease patients
    Bartosova, O.
    Bonnet, C.
    Ulmanova, O.
    Sima, M.
    Perlik, F.
    Ruzicka, E.
    Slanar, O.
    JOURNAL OF NEURAL TRANSMISSION, 2018, 125 (04) : 699 - 703
  • [7] Monitoring of L-dopa concentrations in Parkinson's disease
    Furlanut, M
    Furlanut, M
    Benetello, P
    PHARMACOLOGICAL RESEARCH, 2001, 43 (05) : 423 - 427
  • [8] Conversion of L-dopa to Extended Release L-dopa (Rytary®) in Patients with Fluctuating Parkinson's Disease: Predictors of Dose
    Ondo, William
    Coss, Pablo
    Christie, Melissa
    Pascual, Belen
    JOURNAL OF PARKINSONS DISEASE, 2019, 9 (01) : 153 - 156
  • [9] Peculiarities of L-DOPA treatment of Parkinson's disease
    Kostrzewa, RM
    Nowak, P
    Kostrzewa, JP
    Kostrzewa, RA
    Brus, R
    AMINO ACIDS, 2005, 28 (02) : 157 - 164
  • [10] Entacapone and selegiline with L-dopa in patients with Parkinson's disease:: an interaction study
    Lyytinen, J
    Kaakkola, S
    Gordin, A
    Kultalahti, ER
    Teräväinen, H
    PARKINSONISM & RELATED DISORDERS, 2000, 6 (04) : 215 - 222
12345